Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescent sentinel lymph node identification in colon cancer using submucosal bevacizumab-800CW
NL-OMON51330Active, not recruiting
- Sponsor
- Meander Medical Center
- Start
- Sep 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab-IRDye800CW in colon cancer, sponsored by Meander Medical Center. Primary endpoints: Identification rate of sentinel lymph nodes or lymph node metastases with bevacizumab-800CW and Rate of adverse events related to bevacizumab-800CW. Started Sep 2022; status: active, not recruiting.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
colon cancer
Beyond the preview
Go deeper on NL-OMON51330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51330.